LIFECORE BIOMEDICAL, INC. \DE\ LFCR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-1.75
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $128.9M | -$38.7M | $40.3M | -$13.6M | $1.3M |
| 2024 | $128.3M | $12.0M | $41.9M | -$18.1M | $11.3M |
| 2023 | $103.3M | -$99.6M | $28.0M | — | -$4.2M |
| 2022 | $111.3M | -$116.7M | $39.1M | -$48.8M | $87.8M |
| 2021 | $100.9M | -$32.3M | $38.9M | -$2.8M | $201.9M |
| 2020 | $160.1M | -$38.2M | $39.4M | -$29.3M | $229.8M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.75 (distress)
- Working capital / assets 0.232
- Retained earnings / assets -0.858
- EBIT / assets -0.072
- Equity / liabilities 0.007
Source: SEC EDGAR filings · CIK 0001005286 · as of 2025-05-25. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.